Assessing the role of LRRCl5 as a prognostic and therapeutic biomarker in glioblastoma.

OBJECTIVES

Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by rapid progression and poor prognosis. Identifying novel biomarkers and therapeutic targets is crucial for improving GBM outcomes. This study aimed to explore the expression, prognostic value, therapeutic significance, and functional role of Leucine-Rich Repeat Containing 15 (LRRC15) in GBM.

METHODS

We utilized data from multiple online databases to analyze LRRC15 expression and its prognostic significance. Mutational and methylation profiles were examined, followed by survival analyses. Experimental validation was conducted using reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western blotting in GBM cell lines. Functional assays, including colony formation, proliferation, and wound healing, were used to assess the effects of LRRC15 knockdown.

RESULTS

LRRC15 expression was significantly elevated in GBM. High LRRC15 levels were associated with shorter overall survival (OS) and disease-free survival (DFS) in GBM patients. Methylation analysis indicated that promoter hypermethylation may regulate LRRC15 expression. Knockdown of LRRC15 in GBM cell lines led to reduced cell proliferation, colony formation, and migration, along with a reversal of epithelial-mesenchymal transition (EMT), characterized by decreased N-cadherin and vimentin and increased E-cadherin expression.

CONCLUSION

LRRC15 is highly expressed in GBM and correlates with poor patient prognosis. Its role in enhancing cell proliferation, migration, and EMT suggests that LRRC15 contributes to GBM aggressiveness. These findings highlight LRRC15 as a promising biomarker and potential therapeutic target for GBM, warranting further investigation into LRRC15-targeted therapies.